Catalent Achieves Global ISO Accreditation, Becomes One of the First Contract Development and Manufacturing Organizations to Receive Award

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that the British Standards Institute (BSI) has awarded Catalent a global accreditation against the international management standards for environment (ISO14001:2015) and Occupational Safety (OHSAS18001:2007). The accreditation, for Catalent’s global Environment, Health & Safety (EHS) management system is one of the first to be awarded in the pharmaceutical industry to a contract development and manufacturing organization (CDMO).

SOMERSET, N.J. (PRWEB) May 09, 2019 -- Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that the British Standards Institute (BSI) has awarded Catalent a global accreditation against the international management standards for environment (ISO14001:2015) and Occupational Safety (OHSAS18001:2007). The accreditation, for Catalent’s global Environment, Health & Safety (EHS) management system is one of the first to be awarded in the pharmaceutical industry to a contract development and manufacturing organization (CDMO).

BSI’s auditors judged that Catalent’s EHS system demonstrates a high-degree of sophistication and maturity and competes at a world-class performance level with other leading industries and businesses.

“Our EHS system drives our core values of injury prevention and environmental sustainability, and is central to supporting customer and patient expectations,” commented Mark Incledon, Catalent’s Global Director, EHS. He added, “This accreditation is very much in line with Catalent's patient-first and corporate responsibility-driven philosophy, while helping us meet our environmental targets and promote a cleaner planet.”

Catalent’s global network of facilities produce over 70 billion doses annually and are approved by 35 regulatory agencies to provide flexible commercial and clinical manufacturing supplies in oral, sterile, biologic and inhaled dose forms for customers around the world.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With more than 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

Contact Information
Chris Halling
Catalent
http://www.catalent.com
+44 7580 041073

Richard Kerns
Northern Exposure Public Relations
http://www.nepr.agency
+44 161 728 5880

Online Web 2.0 Version
You can read the online version of this press release here.